Website value calculator & SEO Checker => ionispharma.com
SEO report with information and free domain appraisal for ionispharma.com. It is a domain hosted in . Its server is hosted on IP 146.148.34.142. The domain is ranked at the number 555529 as a world ranking of web pages. According to estimated data we have access to potential gains of this site are 110 dollars per month. In annual terms, the domain ionispharma.com could be earning more than 1323 dollars. If someone wanted to buy the domain a good selling price would be 13225 dollars.
These data are estimated and can not be taken as 100 % real. Only give an estimate of profits depending on the subject and the traffic generated by ionispharma.com . The estimated number of unique visitors accessing ionispharma.com is 963. Thus the total number of people who visit this page per month would be 28889 people.
Domain Authority
SEO Score
☰ Report Resume
- SEO score
- Speed
- Page Load Time
- Current Ip of the domain: 146.148.34.142
- Charset of page: UTF-8
- Total Keywords: 868
- Total Links: Anchor textTypeLinkSkip to contentfollow#contentfollowhttps://www.ionispharma.comHomefollowhttps://www.ionispharma.com/Aboutfollowhttps://www.ionispharma.com/about/Back To Mainfollow#Ionis: A force for lifefollow/about/#forceExecutive & Leadership Teamfollow/about/#teamBoard of Directorsfollow/about/#teamAkcea Therapeuticsfollow/about/#akceaIonis Innovationfollowhttps://www.ionispharma.com/ionis-innovation/antisense-technology/Back To Mainfollow#Antisense Technologyfollowhttps://www.ionispharma.com/ionis-innovation/antisense-technology/Optimizing Antisensefollowhttps://www.ionispharma.com/ionis-innovation/optimizing-antisense/Pipelinefollowhttps://www.ionispharma.com/ionis-innovation/pipeline/Ion-ARPA Initiativefollowhttps://www.ionispharma.com/ionis-innovation/ion-arpa-initiative/Our Medicinesfollowhttps://www.ionispharma.com/our-medicines/Patients & Communityfollowhttps://www.ionispharma.com/patients-community/Back To Mainfollow#Overviewfollowhttps://www.ionispharma.com/patients-community/Patient Resourcesfollowhttps://www.ionispharma.com/patients-community/patient-resources/Community Engagementfollowhttps://www.ionispharma.com/patients-community/community-engagement/Patient Experiencesfollowhttps://www.ionispharma.com/patients-community/patient-experiences/Investors & mediafollowhttps://ir.ionispharma.com/Back To Mainfollow#Overviewfollowhttps://ir.ionispharma.com/Newsroomfollowhttp://ir.ionispharma.com/news-releasesBack To Mainfollow#Investors & Mediafollow#Press Releasesfollowhttp://ir.ionispharma.com/news-releasesInBriefsfollowhttps://ir.ionispharma.com/inbriefsMedia Centerfollowhttps://www.ionispharma.com/media-center/Stock Informationfollowhttp://ir.ionispharma.com/stock-information/stock-quoteBack To Mainfollow#Investors & Mediafollow#Stock Quote & Chartfollowhttp://ir.ionispharma.com/stock-information/stock-quoteAnalyst Coveragefollowhttp://ir.ionispharma.com/stock-information/analyst-coverageOwnership Profilefollowhttp://ir.ionispharma.com/stock-information/institutional-ownershipFinancialsfollowhttp://ir.ionispharma.com/financial-information/sec-filingsBack To Mainfollow#Investors & Mediafollow#SEC Filingsfollowhttp://ir.ionispharma.com/financial-information/sec-filingsAnnual Reportsfollowhttp://ir.ionispharma.com/financial-information/annual-reportsGovernancefollowhttp://ir.ionispharma.com/corporate-governance/highlightsBack To Mainfollow#Investors & Mediafollow#Governance Documentsfollowhttp://ir.ionispharma.com/corporate-governance/highlightsCommittee Compositionfollowhttp://ir.ionispharma.com/corporate-governance/committee-compositionInvestor Resourcesfollowhttp://ir.ionispharma.com/shareholder-services/investor-faqsBack To Mainfollow#Investors & Mediafollow#Investor FAQsfollowhttp://ir.ionispharma.com/shareholder-services/investor-faqsContact Usfollowhttp://ir.ionispharma.com/shareholder-services/contact-irEventsfollowhttp://ir.ionispharma.com/events-and-presentations/upcoming-eventsBack To Mainfollow#Investors & Mediafollow#Eventsfollowhttp://ir.ionispharma.com/events-and-presentations/upcoming-eventsCareersfollowhttps://www.ionispharma.com/careers/Back To Mainfollow#Overviewfollowhttps://www.ionispharma.com/careers/Working at Ionisfollowhttps://www.ionispharma.com/careers/working-at-ionis/Employee Spotlightfollowhttps://www.ionispharma.com/careers/employee-spotlight/Volunteerism & Philanthropyfollowhttps://www.ionispharma.com/careers/volunteerism-philanthropy/Investments in Youfollowhttps://www.ionispharma.com/careers/investments-in-you/Intern Programfollowhttps://www.ionispharma.com/careers/intern-program/Postdoctoral Programfollowhttps://www.ionispharma.com/careers/post-doctoral/.cls-social-linkedin{fill:#a4a3a4}followhttps://www.linkedin.com/company/ionis-pharmaceuticals.cls-social-twitter{fill:#a4a3a4}twitter-greyfollowhttps://twitter.com/ionispharma?lang=en.cls-social-facebook{fill:#a4a3a4}facebook-greyfollowhttps://www.facebook.com/Ionis-Pharmaceuticals-108946637429610followhttps://www.ionispharma.comHomefollowhttps://www.ionispharma.com/Aboutfollowhttps://www.ionispharma.com/about/Back To Mainfollow#Ionis: A force for lifefollow/about/#forceExecutive & Leadership Teamfollow/about/#teamBoard of Directorsfollow/about/#teamAkcea Therapeuticsfollow/about/#akceaIonis Innovationfollowhttps://www.ionispharma.com/ionis-innovation/antisense-technology/Back To Mainfollow#Antisense Technologyfollowhttps://www.ionispharma.com/ionis-innovation/antisense-technology/Optimizing Antisensefollowhttps://www.ionispharma.com/ionis-innovation/optimizing-antisense/Pipelinefollowhttps://www.ionispharma.com/ionis-innovation/pipeline/Ion-ARPA Initiativefollowhttps://www.ionispharma.com/ionis-innovation/ion-arpa-initiative/Our Medicinesfollowhttps://www.ionispharma.com/our-medicines/Patients & Communityfollowhttps://www.ionispharma.com/patients-community/Back To Mainfollow#Overviewfollowhttps://www.ionispharma.com/patients-community/Patient Resourcesfollowhttps://www.ionispharma.com/patients-community/patient-resources/Community Engagementfollowhttps://www.ionispharma.com/patients-community/community-engagement/Patient Experiencesfollowhttps://www.ionispharma.com/patients-community/patient-experiences/Investors & mediafollowhttps://ir.ionispharma.com/Back To Mainfollow#Overviewfollowhttps://ir.ionispharma.com/Newsroomfollowhttp://ir.ionispharma.com/news-releasesBack To Mainfollow#Investors & Mediafollow#Press Releasesfollowhttp://ir.ionispharma.com/news-releasesInBriefsfollowhttps://ir.ionispharma.com/inbriefsMedia Centerfollowhttps://www.ionispharma.com/media-center/Stock Informationfollowhttp://ir.ionispharma.com/stock-information/stock-quoteBack To Mainfollow#Investors & Mediafollow#Stock Quote & Chartfollowhttp://ir.ionispharma.com/stock-information/stock-quoteAnalyst Coveragefollowhttp://ir.ionispharma.com/stock-information/analyst-coverageOwnership Profilefollowhttp://ir.ionispharma.com/stock-information/institutional-ownershipFinancialsfollowhttp://ir.ionispharma.com/financial-information/sec-filingsBack To Mainfollow#Investors & Mediafollow#SEC Filingsfollowhttp://ir.ionispharma.com/financial-information/sec-filingsAnnual Reportsfollowhttp://ir.ionispharma.com/financial-information/annual-reportsGovernancefollowhttp://ir.ionispharma.com/corporate-governance/highlightsBack To Mainfollow#Investors & Mediafollow#Governance Documentsfollowhttp://ir.ionispharma.com/corporate-governance/highlightsCommittee Compositionfollowhttp://ir.ionispharma.com/corporate-governance/committee-compositionInvestor Resourcesfollowhttp://ir.ionispharma.com/shareholder-services/investor-faqsBack To Mainfollow#Investors & Mediafollow#Investor FAQsfollowhttp://ir.ionispharma.com/shareholder-services/investor-faqsContact Usfollowhttp://ir.ionispharma.com/shareholder-services/contact-irEventsfollowhttp://ir.ionispharma.com/events-and-presentations/upcoming-eventsBack To Mainfollow#Investors & Mediafollow#Eventsfollowhttp://ir.ionispharma.com/events-and-presentations/upcoming-eventsCareersfollowhttps://www.ionispharma.com/careers/Back To Mainfollow#Overviewfollowhttps://www.ionispharma.com/careers/Working at Ionisfollowhttps://www.ionispharma.com/careers/working-at-ionis/Employee Spotlightfollowhttps://www.ionispharma.com/careers/employee-spotlight/Volunteerism & Philanthropyfollowhttps://www.ionispharma.com/careers/volunteerism-philanthropy/Investments in Youfollowhttps://www.ionispharma.com/careers/investments-in-you/Intern Programfollowhttps://www.ionispharma.com/careers/intern-program/Postdoctoral Programfollowhttps://www.ionispharma.com/careers/post-doctoral/.cls-social-linkedin{fill:#a4a3a4}followhttps://www.linkedin.com/company/ionis-pharmaceuticals.cls-social-twitter{fill:#a4a3a4}twitter-greyfollowhttps://twitter.com/ionispharma?lang=en.cls-social-facebook{fill:#a4a3a4}facebook-greyfollowhttps://www.facebook.com/Ionis-Pharmaceuticals-108946637429610Continue to sitefollow#Cancelfollow#followLearn more about our Ionis Innovationsfollow/ionis-innovation/See who inspires usfollow/patients-community/patient-experiences/Review our pipelinefollow/ionis-innovation/pipeline/View all press releasesfollowhttp://ir.ionispharma.com/news-releasesOct 20 Ionis to hold third quarter 2021 financial results webcast.cls-orange{fill:none;stroke:#ea7425;stroke-miterlimit:10;}orange-arrowfollowhttp://ir.ionispharma.com/news-releases/news-release-details/ionis-hold-third-quarter-2021-financial-results-webcastOct 17 Ionis’ partner Biogen provides update on tofersen Phase 3 VALOR study in SOD1-ALS.cls-orange{fill:none;stroke:#ea7425;stroke-miterlimit:10;}orange-arrowfollowhttp://ir.ionispharma.com/news-releases/news-release-details/ionis-partner-biogen-provides-update-tofersen-phase-3-valorOct 14 Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS to be Presented at the American Neurological Association Annual Meeting.cls-orange{fill:none;stroke:#ea7425;stroke-miterlimit:10;}orange-arrowfollowhttp://ir.ionispharma.com/news-releases/news-release-details/topline-results-tofersen-phase-3-study-and-its-open-labelherefollow/careers/how-to-identify-fake-job-advertisements/Join our teamfollow/careers/Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at further advancing LICA technologyfollowhttps://ir.ionispharma.com/news-releases/news-release-details/ionis-enters-exclusive-licensing-agreement-bicycle-therapeuticsIonis to hold second quarter 2021 financial results webcastfollowhttps://ir.ionispharma.com/news-releases/news-release-details/ionis-hold-second-quarter-2021-financial-results-webcastBiogen and Ionis report positive topline clinical data on investigational Alzheimer"s disease treatment at AAICfollowhttps://ir.ionispharma.com/news-releases/news-release-details/biogen-and-ionis-report-positive-topline-clinical-dataIonis completes enrollment in pivotal NEURO-TTRansform study of eplontersenfollowhttp://Ionis completes enrollment in pivotal NEURO-TTRansform study of eplontersenIonis" partner Biogen provides update on tofersen Phase 3 VALOR study in SOD1-ALSfollowhttps://ir.ionispharma.com/news-releases/news-release-details/ionis-partner-biogen-provides-update-tofersen-phase-3-valorContactfollowhttps://www.ionispharma.com/contact-us/Suppliersfollowhttps://www.ionispharma.com/suppliers/Legal Noticefollowhttps://www.ionispharma.com/legal-notice/Privacy Policyfollowhttps://www.ionispharma.com/privacy-policy/Social Media Policiesfollowhttps://www.ionispharma.com/social-policies/Powered by GDPR Cookie Compliancefollowhttps://wordpress.org/plugins/gdpr-cookie-compliance
- Social signals
- Title: 34 characters.
- Description: 146 characters.
- Domain Authority
- Monthly pages viewed: 28889
- Estimated worth: 13225 dollars
We have developed a useful service for retrieve WhoIs information. "Whois" is a term that begins from the early days of the Internet, based on Unix operating system and university networks. On the Unix console, the command "whois" tries to determine the identity of the domain's registrant.
It is a means for Internet users to query various types of information such as IP addresses, user data and also domain data.
✦ SEO Report
Title / Meta tags
Home | Ionis Pharmaceuticals, Inc.
As the leader in RNA-targeted therapeutics, our antisense technology treats illnesses where no other therapeutic approaches have proven effective.
Image Analysis
A right example for an HTML image tag:
<img src="prettyimage.jpg" alt="image description" title="image tooltip"/>
For SEO performance, you must write an alternative text. The alternative text must describe the image's content. Also, the alt tag is used for blind people. Their browsers tell them all about the description of the image.
Heading
Content Analysis
Code Analysis
We have not found hyphens (-) or underscores (_) in your URL. Google and expert domainers do not recommend buying domains with hyphens or underscores.
When a visitor came to your website you can not fail. The user wants your page to load in a second. You know that it is difficult sometimes to display content in the first second but if the user has to wait too much time you can lose that user. If your page is too slow, you will lose a lot of web traffic. Your project URL load time is ms, it is class speed. This speed not fine and need to be improved. It is over the average. Our Speed analyzer has shown that www.ionispharma.com is as follows:
A huge portion of visitors to your website are usually in rush and nobody is fond of waiting too much before your website loads its content. If your website is slow, you will lose a lot of visitors. Your homepage load time is ms is class speed. This speed not fine and need to be improved. It is over the average. Our Speed analyzer has shown that www.ionispharma.com is as follows:
Speed:
Page Load Time: ms
saswp-schema-markup-output, home page-template-default page page-id-2 chrome desktop-device windows, site, sr-only sr-only-focusable, main-header, container, inner, logo, main-menu-wrapper, menu main-menu, menu-list, d-lg-none menu-item menu-item-type-post_type menu-item-object-page menu-item-home current-menu-item page_item page-item-2 current_page_item menu-item-51, menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-69, sub-menu, sub-menu-back menu-item menu-item-type-custom menu-item-object-custom menu-item-3185, menu-item menu-item-type-custom menu-item-object-custom menu-item-3186, menu-item menu-item-type-custom menu-item-object-custom menu-item-3187, menu-item menu-item-type-custom menu-item-object-custom menu-item-3188, menu-item menu-item-type-custom menu-item-object-custom menu-item-3189, menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-2833, sub-menu-back menu-item menu-item-type-custom menu-item-object-custom menu-item-52, menu-item menu-item-type-post_type menu-item-object-page menu-item-531, menu-item menu-item-type-post_type menu-item-object-page menu-item-532, menu-item menu-item-type-post_type menu-item-object-page menu-item-539, menu-item menu-item-type-post_type menu-item-object-page menu-item-3273, menu-item menu-item-type-post_type menu-item-object-page menu-item-540, menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-1969, sub-menu-back menu-item menu-item-type-custom menu-item-object-custom menu-item-53, menu-item menu-item-type-post_type menu-item-object-page menu-item-689, menu-item menu-item-type-post_type menu-item-object-page menu-item-691, menu-item menu-item-type-post_type menu-item-object-page menu-item-690, menu-item menu-item-type-post_type menu-item-object-page menu-item-692, menu-item-has-submenus-with-children menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-25, sub-menu-back menu-item menu-item-type-custom menu-item-object-custom menu-item-60, menu-item menu-item-type-custom menu-item-object-custom menu-item-26, menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-27, sub-menu-back menu-item menu-item-type-custom menu-item-object-custom menu-item-59, back-to-main menu-item menu-item-type-custom menu-item-object-custom menu-item-65, menu-item menu-item-type-custom menu-item-object-custom menu-item-29, menu-item menu-item-type-custom menu-item-object-custom menu-item-2738, menu-item menu-item-type-post_type menu-item-object-page menu-item-583, menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-31, sub-menu-back menu-item menu-item-type-custom menu-item-object-custom menu-item-58, back-to-main menu-item menu-item-type-custom menu-item-object-custom menu-item-66, menu-item menu-item-type-custom menu-item-object-custom menu-item-32, menu-item menu-item-type-custom menu-item-object-custom menu-item-33, menu-item menu-item-type-custom menu-item-object-custom menu-item-34, menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-35, sub-menu-back menu-item menu-item-type-custom menu-item-object-custom menu-item-57, back-to-main menu-item menu-item-type-custom menu-item-object-custom menu-item-64, menu-item menu-item-type-custom menu-item-object-custom menu-item-36, menu-item menu-item-type-custom menu-item-object-custom menu-item-37, menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-38, sub-menu-back menu-item menu-item-type-custom menu-item-object-custom menu-item-56, back-to-main menu-item menu-item-type-custom menu-item-object-custom menu-item-63, menu-item menu-item-type-custom menu-item-object-custom menu-item-39, menu-item menu-item-type-custom menu-item-object-custom menu-item-40, menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-43, sub-menu-back menu-item menu-item-type-custom menu-item-object-custom menu-item-54, back-to-main menu-item menu-item-type-custom menu-item-object-custom menu-item-62, menu-item menu-item-type-custom menu-item-object-custom menu-item-44, menu-item menu-item-type-custom menu-item-object-custom menu-item-45, menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-46, sub-menu-back menu-item menu-item-type-custom menu-item-object-custom menu-item-55, back-to-main menu-item menu-item-type-custom menu-item-object-custom menu-item-61, menu-item menu-item-type-custom menu-item-object-custom menu-item-47, menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-1968, sub-menu-back menu-item menu-item-type-custom menu-item-object-custom menu-item-544, menu-item menu-item-type-post_type menu-item-object-page menu-item-533, menu-item menu-item-type-post_type menu-item-object-page menu-item-543, menu-item menu-item-type-post_type menu-item-object-page menu-item-2941, menu-item menu-item-type-post_type menu-item-object-page menu-item-3388, menu-item menu-item-type-post_type menu-item-object-page menu-item-2845, menu-item menu-item-type-post_type menu-item-object-page menu-item-541, menu-item menu-item-type-post_type menu-item-object-page menu-item-542, search-wrapper, search-form, search-box, close-button, search-icon, social-wrap, icons-wrap, social-icon linkedin, cls-social-linkedin, social-icon twitter, cls-social-twitter, social-icon facebook, cls-social-facebook, logo-wrapper, main-menu-open, line line-1, line line-2, line line-3, text, top-menu, main-menu-close, navigation-wrapper, interstitial-popup mfp-hide, interstitial-popup__close, mfp-close, interstitial-popup__text, interstitial-popup__target, interstitial-popup__buttons, interstitial-popup__buttons__continue btn btn--gradient btn--size-small, interstitial-popup__buttons__cancel color--orange weight-bold base, site-content, content-area, site-main, hero-section hero-section--home, container-fluid, row justify-content-center, hero-section__text offset-1 col-9 offset-md-1 col-md-6 col-lg-5 color--white, hero-section__title, weight-black, color--secondary, hero-section__subtitle md weight-medium, hero-section__wing, banner-section, row, banner-section__link, text-and-image-section, row justify-content-end align-items-center, image-wrapper col-12 col-md-6, text-content col-12 col-md-6 col-contained position-right, text-content__border, text-content__wrapper, text-content__title color--secondary, text-content__text, text-content__link, link, full-width-section section-with-separator, text-content color--white col-9 col-md-6, text-content__title, col-12, text-content__button, btn btn--gradient btn--size-small, press-section, press-section__wrapper col-12, press-section__header, press-section__title color--white, press-section__link link, press-list, press-list__item, press-list__item-date, press-list__item-title, cls-orange, ticker-section, ticker, ticker__title, ticker__content, MS-content, ticker__content__item item, ticker__content__item__link , main-footer, footer-column footer-content col-12 col-md-8, footer-menu-wrapper, copyright, widget widget_text, textwidget, widget widget_nav_menu, menu-footer-container, menu, menu-item menu-item-type-post_type menu-item-object-page menu-item-631, menu-item menu-item-type-post_type menu-item-object-page menu-item-1807, menu-item menu-item-type-post_type menu-item-object-page menu-item-587, menu-item menu-item-type-post_type menu-item-object-page menu-item-586, menu-item menu-item-type-post_type menu-item-object-page menu-item-2368, right-lines, moove-gdpr-info-bar-hidden moove-gdpr-align-center moove-gdpr-dark-scheme gdpr_infobar_postion_bottom, moove-gdpr-info-bar-container, moove-gdpr-info-bar-content, moove-gdpr-cookie-notice, change-settings-button, moove-gdpr-button-holder, mgbutton moove-gdpr-infobar-allow-all, gdpr_lightbox-hide, moove-gdpr-modal-content moove-clearfix logo-position-left moove_gdpr_modal_theme_v1, moove-gdpr-modal-close, gdpr-sr-only, gdpr-icon moovegdpr-arrow-close, moove-gdpr-modal-left-content, moove-gdpr-company-logo-holder, img-responsive, menu-item-on menu-item-privacy_overview menu-item-selected, moove-gdpr-tab-nav, gdpr-svg-icon, icon icon-privacy-overview, gdpr-nav-tab-title, menu-item-strict-necessary-cookies menu-item-off, icon icon-strict-necessary, moove-gdpr-branding-cnt, moove-gdpr-branding, moove-gdpr-modal-right-content, moove-gdpr-modal-title, main-modal-content, moove-gdpr-tab-content, moove-gdpr-tab-main, tab-title, moove-gdpr-tab-main-content, moove-gdpr-status-bar , gdpr-cc-form-wrap, gdpr-cc-form-fieldset, cookie-switch, cookie-slider cookie-round, moove-gdpr-strict-warning-message, moove-gdpr-modal-footer-content, mgbutton moove-gdpr-modal-allow-all button-visible, mgbutton moove-gdpr-modal-save-settings button-visible, moove-clearfix,
How much money does ionispharma.com earn?
The domain ionispharma.com has a revenue of $101.1115 monthly. We have calculated this earning based on the daily traffic of this domain.
Has ionispharma.com Google Analytics code?
The domain ionispharma.com has not the Google Analytics code inside its HTML.
Has ionispharma.com Google Adsense code?
The domain ionispharma.com has not the Google Adsense code inside its HTML.
What IP ionispharma.com has?
The domain ionispharma.com has IP 146.148.34.142.
Which charset ionispharma.com has?
An IP address is a string of numbers used to make devices accessible for communication.
The domain ionispharma.com has the charset UTF-8.
How many internal links ionispharma.com has?
To display an HTML page correctly, a web browser must know which character set to use.
The charset change for every language set of characters like English, Chinese or Russian.
The domain ionispharma.com has 0 links.
How many words ionispharma.com has?
The links are an important part of the web.
The links help us to navigate between pages.
The domain ionispharma.com has 868 words.
The number of words is a crucial metric of the website.
The websites need a large quantity of text to explain the content of the site
Last visited